Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ordesekimab - Amgen

Next Previous
Drug Profile

Ordesekimab - Amgen

Alternative Names: AMG-714; Anti-IL-15 MAB; HuMax anti-IL15; HuMax-IL-15; MAb146B7; PRV-015

Latest Information Update: 13 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer Amgen; Celimmune; Immune Tolerance Network; National Institute of Allergy and Infectious Diseases; Provention Bio
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coeliac disease; Vitiligo
  • Discontinued Inflammation; Lymphoma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 13 Jun 2025 National Institute of Allergy and Infectious Diseases, with Amgen and Immune Tolerance Network completes a phase IIa trial in Vitiligo (In adults, In elderly) in USA (SC) (NCT04338581)
  • 04 May 2025 Amgen completes an expanded-access programme for Coeliac disease (NCT03439475)
  • 30 Jul 2024 Provention Bio completes a phase-IIb PROACTIVE trial in Coeliac disease in USA, Netherlands, Canada, Spain (SC) (NCT04424927) (EudraCT2020-000649-16)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top